VERAXA Biotech Secures $77.5M for Upcoming SPAC Merger

Zurich, Switzerland - VERAXA Biotech AG (the Company), an emerging leader in cancer therapy design, has announced a significant financial strengthening ahead of its anticipated business combination with Voyager Acquisition Corp. (Nasdaq: VACH). The company has secured $27.5 million through a senior secured note financing and an additional $50 million via a share purchase agreement (SPA), aimed at advancing its clinical development programs.

The capital infusion provides the financial flexibility necessary to propel VERAXA's pipeline of BiTAC-TCE and BiTAC-ADC programs. These therapies represent next-generation approaches to cancer treatment. The funding is expected to support the company through initial value inflection points as it continues its transition into a publicly traded entity on the Nasdaq Capital Market under the ticker symbol VRXA.

... Read on — Members only